The team tested a variety of types, but found this mechanism at work in KRAS-dependent cancers (so named for the mutated oncogene that drives them). Still, the initial results could have a ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

KRAS is the most frequently mutated oncogene in human cancer and drives the disease in up to 50% of patients with CRC, according to BMS. The KRAS G12C mutation occurs in approximately 3% to 4% of ...

KRAS is one of the most frequently mutated oncogenes in human cancer. Despite more than three decades of research, indirect approaches targeting KRAS-mutant cancers have largely failed to show ...

KRAS is one of the most frequently mutated oncogenes – a gene which, when mutated, can turn normal cells into cancerous ones in humans. It occurs in approximately 90% of pancreatic cancers and ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...